Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: JoeinIowa who wrote (9577)	10/17/1998 8:46:00 PM
From: Sergio H	Read Replies (2) \| Respond to of 29382

Joe, moving your family away from the madness that has overtaken Tuvalu was a grand decision and I applaud you and your move. YYYYYYYYYYYYEEEEEEEEEEEEEEEEHHHHHHHHHHHAAAAA!!!!!!!!!!!!!!!!!!!!!!! ............as we say in these parts. CORR has bounced nicely off the support at 7. I still think that biotechs are the safest sector to be in right now. I came across this write-up in Worth's : Jim McCamant MEDICAL TECHNOLOGY STOCK LETTER Berkeley, California Focuses primarily on small biotechnology companies. COR THERAPEUTICS UP TO $18 Nasdaq: CORR Cardiovascular diseases--heart attacks and strokes--kill roughly one million Americans every year. COR Therapeutics (South San Francisco, California) develops pharmaceutical treatments for the prevention and treatment of severe cardiovascular disease. COR's recently approved drug, Integrilin (which was developed with partner Schering-Plough), is used to prevent blood clots in patients with critical heart conditions and is the only cardiovascular drug approved for both coronary angioplasty and unstable angina. Even with conservative estimates of Integrilin's sales, revenue from the drug should help COR become profitable in 1999. We also expect management to move aggressively to license other cardiovascular drugs. With the anticipation of strong sales, $100 million in the bank, and further substantial funding possible from Schering, COR is a steal at current prices.